From Protein Dynamics to Drug Design: Folding@home Helps Develop New RIPK1 Degraders

RIPK1 is a protein that plays an important role in regulating cell survival and cell death. It has attracted increasing interest as a potential drug target because of its role in inflammatory diseases and cancer. In particular, some cancer cells use RIPK1 to evade the immune system and promote their survival. While conventional drugs can inhibit RIPK1's kinase activity, they cannot eliminate its other functions that help cancer cells survive. This makes RIPK1 an interesting target for a different approach: removing the protein entirely.

A promising strategy, known as targeted protein degradation (TPD), uses small molecules called PROTACs (Proteolysis Targeting Chimeras) to eliminate disease-associated proteins rather than simply inhibiting them. PROTACs bring a target protein together with an E3 ligase, a component of the cell's protein recycling machinery, allowing the cell to recognize and destroy the target protein. However, designing effective PROTACs remains challenging because the interactions between these two proteins are often short-lived and difficult to predict.

In our recent study, we used the computing resources of Folding@home to perform approximately 420 microseconds of all-atom molecular dynamics (MD) simulations of RIPK1 interacting with the von Hippel–Lindau (VHL) E3 ligase. By combining these simulations with our Integrative Generalized Master Equation (IGME) method, we identified several short-lived but relatively stable protein–protein interactions (PPIs) that could be exploited for PROTAC design.

Our simulations revealed that different protein–protein interactions favor PROTACs with different linker lengths. This explains why PROTACs with very short and very long linkers can both effectively degrade RIPK1. We then used these findings to guide the design of new PROTAC molecules, including ones that use a previously underexplored attachment site on the VHL ligand.

Working with our experimental collaborators, we synthesized and tested these new molecules. Two distinct PPIs favor either long or short linkers, with both designs showing strong degradation activity experimentally. Notably, the two best compounds achieved complete degradation of RIPK1 in cancer cells at very low concentrations, with sub-nanomolar to low-nanomolar potency.

Our results show how large-scale molecular simulations enabled by Folding@home can help guide the design of new PROTAC drug molecules. Although these compounds are still at an early research stage, this approach may help develop new therapies targeting RIPK1 and other disease-associated proteins.

Many thanks to all Folding@home volunteers who contributed their computing resources to this project! Your contributions made these simulations possible.

Read our paper in JACS Au, 2026:

https://pubs.acs.org/jaaucr/article/6/5/2935/5073403/Metastable-Protein-Protein-Interactions-as-a